TrialBlood2025

Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT.

Eduard Schulz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.